These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 31343662)

  • 21. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
    Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity.
    Moratiel Pellitero A; Zapata Garcia M; Gascon Ruiz M; Arbones-Mainar JM; Lastra Del Prado R; Isla D
    World J Oncol; 2024 Apr; 15(2):223-238. PubMed ID: 38545481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
    Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
    Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade.
    Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Ruggeri EM
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
    Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
    J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.
    Zhang Q; Gong X; Sun L; Miao L; Zhou Y
    Front Oncol; 2022; 12():791496. PubMed ID: 35924149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Arıkan R; Alkış H; Işık S; Yaşar A; Çelebi A; Majidova N; Sever N; Adlı M; Demircan NC
    Cureus; 2023 Jun; 15(6):e40548. PubMed ID: 37465788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors.
    Auclin E; Vuagnat P; Smolenschi C; Taieb J; Adeva J; Nebot-Bral L; Garcia de Herreros M; Vidal Tocino R; Longo-Muñoz F; El Dakdouki Y; Martín-Romano P; Gaba L; Saurí T; Oliveres H; Castañón E; Garcia-Carbonero R; Besse B; Massard C; Mezquita L; Hollebecque A
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359675
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
    Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
    Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
    Meyers DE; Stukalin I; Vallerand IA; Lewinson RT; Suo A; Dean M; North S; Pabani A; Cheng T; Heng DYC; Bebb DG; Morris DG
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis.
    Liu H; Yang XL; Yang XY; Dong ZR; Chen ZQ; Hong JG; Li T
    Front Oncol; 2021; 11():691002. PubMed ID: 34631525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Lung Immune Prognostic Index May Predict the Efficacy of Different Treatments in Patients with Advanced NSCLC: A Meta-Analysis.
    Xie J; Zang Y; Liu M; Peng L; Zhang H
    Oncol Res Treat; 2021; 44(4):164-175. PubMed ID: 33657566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
    Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
    Front Oncol; 2021; 11():690093. PubMed ID: 34150659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
    Qi W; Zhao S; Chen J
    Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score.
    Pan Y; Si H; Jia R; Deng G; Yan H; Fan M; Gou M; Chen S; Zhang N; Shi Y; Qian N; Dai G
    J Oncol; 2022; 2022():1427779. PubMed ID: 35342416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Nakamura K; Ishiyama Y; Nemoto Y; Ishihara H; Tachibana H; Fukuda H; Shinmura H; Hashimoto Y; Yoshida K; Iizuka J; Ishida H; Kondo T; Takagi T
    Int J Clin Oncol; 2023 Jul; 28(7):913-921. PubMed ID: 37103730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.
    Zhou Q; Deng G; Wang Z; Dai G
    Front Surg; 2022; 9():1002075. PubMed ID: 36684178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
    Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis.
    Wang Y; Lei Y; Zheng D; Yang Y; Luo L; Li J; Xie X
    Pathol Oncol Res; 2024; 30():1611773. PubMed ID: 38966280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.